# Clinopodium gracile Alleviates Metabolic Dysfunction-Associated Steatotic Liver Disease by Upregulating Peroxisome Proliferator-Activated Receptor α and Inhibiting Mitochondrial Oxidative Damage

**Authors:** Mingshi Ren, Jiayue Ren, Jianmei Zheng, Xiaotong Sha, Yining Lin, Feihua Wu

PMC · DOI: 10.3390/antiox13091136 · 2024-09-20

## TL;DR

Clinopodium gracile extract may help treat liver disease by boosting fat breakdown and reducing oxidative damage.

## Contribution

CGE shows potential as a new treatment for MASLD by targeting PPARα and mitochondrial health.

## Key findings

- CGE promotes fatty acid oxidation and reduces lipid accumulation in hepatocytes.
- CGE inhibits oxidative stress and maintains mitochondrial function in PA-induced cells.
- In mice, CGE reduces lipid metabolism disorders and upregulates PPARα in the liver.

## Abstract

The most prevalent chronic liver disease, known as metabolic dysfunction-associated steatotic liver disease (MASLD), is characterized by an excessive accumulation of lipids and oxidative damage. Clinopodium gracile, a natural herbal medicine widely used by Chinese folk, has antioxidative, anti-inflammatory, and lipid metabolism-regulating effects. Here, we explored the effect of C. gracile extract (CGE) on MASLD using palmitic acid (PA)-induced hepatocytes and high-fat diet (HFD)-fed mice. In vitro, CGE could promote fatty acid oxidation and inhibit fatty acid synthesis and uptake to reduce lipid accumulation by regulating PPARα activation. Moreover, CGE could inhibit reactive oxygen species production and maintain mitochondrial homeostasis in PA-induced HepG2 cells. In vivo, animal study results indicated that CGE could effectively reduce lipid metabolism disorder, inhibit oxidative stress, and upregulate PPARα protein in the liver of HFD-fed mice. Molecular docking results also showed that active compounds isolated from CGE had low binding energy and highly stable binding with PPARα. In summary, these findings reveal that CGE may be a potential therapeutic candidate for MASLD and act by upregulating PPARα to reduce lipid accumulation and suppress mitochondrial oxidative damage.

## Linked entities

- **Genes:** PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465]
- **Proteins:** PPARA (peroxisome proliferator activated receptor alpha)
- **Chemicals:** palmitic acid (PubChem CID 985), CGE (PubChem CID 60606)
- **Diseases:** metabolic dysfunction-associated steatotic liver disease (MONDO:0013209), MASLD (MONDO:0013209)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}
- **Diseases:** lipid metabolism disorder (MESH:D052439), MASLD (MESH:D008107), Mitochondrial (MESH:D028361), inflammatory (MESH:D007249)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Clinopodium gracile (species) [taxon 1150280]
- **Cell lines:** HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11428588/full.md

---
Source: https://tomesphere.com/paper/PMC11428588